Clinical Trial Update: Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating neoadjuvant hormonal therapy plus palbociclib in operable, hormone receptor–positive, HER2-negative breast cancer has completed recruit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Palbociclib (palbociclib)

Snippet

Sponsor: Kyoto Breast Cancer Research Network | Conditions: Breast Cancer Female, Hormone Receptor Positive Malignant Neoplasm of Breast | Phase 3 | Status: COMPLETED